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Abstract
Introduction: Centralized intake is integral to healthcare systems to support timely access to appropriate health
services. The aim of this study was to develop key performance indicators (KPIs) to evaluate centralized intake systems
for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Methods: Phase 1 involved stakeholder meetings including healthcare providers, managers, researchers and patients to
obtain input on candidate KPIs, aligned along six quality dimensions: appropriateness, accessibility, acceptability,
efficiency, effectiveness, and safety. Phase 2 involved literature reviews to ensure KPIs were based on best practices and
harmonized with existing measures. Phase 3 involved a three-round, online modified Delphi panel to finalize the KPIs.
The panel consisted of two rounds of rating and a round of online and in-person discussions. KPIs rated as valid and
important (≥7 on a 9-point Likert scale) were included in the final set.
Results: Twenty-five KPIs identified and substantiated during Phases 1 and 2 were submitted to 27 panellists including
healthcare providers, managers, researchers, and patients in Phase 3. After the in-person meeting, three KPIs were
removed and six were suggested. The final set includes 9 OA KPIs, 10 RA KPIs and 9 relating to centralized intake
processes for both conditions. All 28 KPIs were rated as valid and important.
Conclusions: Arthritis stakeholders have proposed 28 KPIs that should be used in quality improvement efforts
when evaluating centralized intake for OA and RA. The KPIs measure five of the six dimensions of quality and are
relevant to patients, practitioners and health systems.
Keywords: Osteoarthritis, Rheumatoid arthritis, Health services research
Introduction
Arthritis is the leading cause of physical disability in
Canada and the burden of arthritis, including osteoarth-
ritis (OA) and rheumatoid arthritis (RA), is expected to
increase over the next 30 years [1]. Timely diagnosis and
appropriate treatment are associated with better out-
comes for patients with arthritis. Patients with OA
report less pain and improved quality of life and func-
tion following timely joint arthroplasties [2–4]. In RA, it
is well established that early, targeted treatment with
disease-modifying antirheumatic drugs (DMARDs) is as-
sociated with improved outcomes [5–7], which is a cen-
tral component in evidence-based RA guidelines [8–11].
Unfortunately, many patients with OA and RA in
Canada experience delays in access to care and treat-
ment. The Canadian Institute for Health Information re-
ports that the proportion of patients meeting wait time
benchmarks for elective procedures (including hip and
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knee replacement) have remained largely unchanged
over the last 3 years, and that many patients are not
receiving care within recommended benchmarks [12].
In RA, national wait time data are lacking [13]; how-
ever, provincial studies suggest that access to rheuma-
tologic care may be problematic because of workforce
shortages [14–16].
The reasons for delays in care for appropriate treat-
ment of patients with OA and RA are complex and in-
clude a mismatch between supply and demand for
specialist care in many regions [14–17]. Furthermore, in-
efficiencies at the level of referral and triage can lead to
delays in care [18]. Effective referral and intake manage-
ment of this patient population is needed to ensure that
the needs of patients are addressed in a timely, orga-
nized, transparent and consistent manner.
Centralized intake is a system that facilitates getting
the right patients to the right providers at the right time
by pooling patients into a single queue, assessing the na-
ture and the urgency of referral, and prioritizing access
to care based on the assessment of the referral [19, 20].
Centralized intake systems that incorporate these ele-
ments of single-entry models and wait list management
are key components to wait time reduction strategies
[12]. These strategies have been shown to reduce wait
times for specialty care and to improve the effective use
of healthcare services [20–22].
The objective of the present work was to develop key
performance indicators (KPIs) for use in evaluating cen-
tralized intake systems for arthritis care, starting with
OA and RA. For the purposes of this work, OA KPIs
were focused on those patients with moderate to severe
OA who required either surgical (total hip or knee
arthroplasty) or nonsurgical management (requiring spe-
cialist consultation). The KPIs will be used to measure
system improvements in the following dimensions of
quality taken from the provincial quality framework [23]:
 Appropriateness: whether services are delivered
according to best practices and relevant to user
needs
 Accessibility: whether services are delivered in a
timely manner
 Acceptability: whether services are responsive to
user expectations and preferences
 Effectiveness: whether services are based on
knowledge to achieve the best outcomes
 Efficiency: whether services are optimally used
Methods
The present work is part of a study to improve access to
appropriate and effective arthritis care through collabor-
ation with arthritis stakeholders. The KPIs for centralized
intake of arthritis care were developed over three phases,
as shown in Fig. 1 and described below.
Phase 1: Establishing measurement priorities
A series of arthritis stakeholder meetings were con-
vened to define measurement priorities. Throughout
Fig. 1 Key performance indicator (KPI) development process. OA osteoarthritis, RA rheumatoid arthritis
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this process, the following stakeholder groups were rep-
resented: healthcare providers, managers, researchers, pa-
tients and patient engagement researchers. The following
criteria were used to prioritize KPI development:
1. Perceived impact: Are there identifiable health
benefits to patients who receive care, to care
providers, and to the health system?
2. Provider influence over performance on the KPI: Is
this factor under the control of a care provider, or
can it lead to changes in the healthcare system?
3. Feasibility of measurement: Is the required
information to measure performance available from
data sources (e.g., electronic medical records or
administrative data sets)?
Phase 2: Integrative review of the literature to support
candidate key performance indicators
An integrative review of the literature [24, 25] was con-
ducted to ensure that the 25 candidate KPIs were based
on evidence and/or best practices and that they were
harmonized with any existing published performance
measures. The search strategy is shown in Additional
file 1.
Briefly, the following sources were used to inform and
support KPI development:
1. KPIs pertaining to RA were harmonized with the
Arthritis Alliance of Canada (AAC) system-level
performance measures for inflammatory arthritis
(IA) [26].
2. Existing measures from the Alberta Hip and Knee
Replacement Measurement Framework for
measuring quality of care for hip and knee
arthroplasty [27–29] were considered for inclusion
in the harmonized set.
3. A grey literature search was conducted to identify
existing measures and current guidelines for the
referral and triage of patients with OA and RA by
searching the websites of 33 arthritis organizations
in North America, Europe, the United Kingdom and
Australia.
4. We updated a recent systematic review of the
literature conducted by the European
Musculoskeletal Conditions Surveillance and
Information Network [30] in two literature
databases (MEDLINE and Embase) to identify all
existing performance measures for OA and RA.
Phase 3: Online arthritis stakeholder panel to finalize
indicators
To finalize the KPIs, a modification of the RAND-UCLA
Appropriateness Method [31] was used during a three-
round, online, modified Delphi procedure using an on-
line platform called ExpertLens [32, 33].
Panel composition and recruitment
Twenty-eight panellists were invited to take part in
Phase 3 of KPI development. All members of the panel
were from Alberta, and they included healthcare pro-
viders (including rheumatologists, orthopaedic surgeons,
primary care physicians and triage personnel), managers
(including clinic managers and health administrators),
and researchers and patients, including some who are
trained in patient and community engagement research.
Panellists were recruited to ensure representation from
the major arthritis care centres as well as from large pri-
mary care networks and patient groups from across Al-
berta. No honoraria or incentives were offered for
participation. The University of Calgary Conjoint Health
Research Ethics Board approved this study (REB13-
0822_MOD5), and the RAND Corporation’s Human
Subjects Protection Committee exempted the study from
review (study identifier 2015-0005). The participants in
this study provided consent to participate and for us to
publish the study findings.
Panel protocol
In round 1, panellists rated the candidate KPIs an-
onymously using the online ExpertLens platform. In
round 2, panellists reviewed the results of the round 1
voting and were given the opportunity to participate
anonymously in an asynchronous online discussion
about the candidate KPIs. Following this, an in-person
meeting was held to review votes and comments on
each KPI from rounds 1 and 2. By consensus, some
KPIs were removed and others were modified or added
to better reflect the measurement priorities. Minor
modifications to wording or specification of the
remaining KPIs were made. In round 3, panellists voted
again on the modified KPI set using the same questions
asked in round 1.
After reviewing a background document that de-
scribed the KPI development process, rationale for
measurement, and supporting information, the panellists
rated each KPI based on the following criteria on a 9-point
Likert-type rating scale:
1. Scientific validity: How strong is either the scientific
evidence or professional consensus supporting this
indicator?
2. Face validity: How likely is it that better
performance on the proposed indicator reflects a
higher-quality health system?
3. Feasibility: How likely is it that the information
required to report on this indicator will be available
in your health system?
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4. Importance: How important is it to measure and
report on this indicator when evaluating centralized
intake for arthritis care?
5. Likelihood of use: How likely is it that you would
use, or encourage the use of, this indicator for
quality improvement in your centre?
For the KPIs that were harmonized with the AAC per-
formance measures, validity was already established
using a similar process [26]; therefore, participants were
asked to answer only questions 3, 4 and 5.
Analysis of panellist responses
To be included in the final set, the KPIs had to be rated
as highly scientifically valid and of high importance
(questions 1 and 4, median ratings ≥7 on a 9-point scale
with no disagreement). Disagreement was calculated ac-
cording to the RAND/UCLA Appropriateness Method
handbook [31]. Disagreement exists when the interpercen-
tile range (IPR) (difference between the 30th and 70th per-
centiles) is larger than the Interpercentile Range Adjusted
for Symmetry (IPRAS), which was calculated using the
formulae: IPRAS = 2.35 + [asymmetry index (AI) × 1.5]
[31], where the AI is the absolute difference between 5
and the central point of the IPR (IPRCP) [31, 34].
Similarly, to include the KPIs that were harmonized
with the AAC measures in the final set, there had to be
agreement on the importance and likelihood of use
(median ratings ≥7 on a 9-point scale).
The feasibility of measuring and reporting on all the
identified KPIs will be tested in later studies and may
vary for different centres within Alberta. Thus, high
feasibility (median ratings ≥7 without disagreement) was
not a requirement for inclusion in the final set. However,
where there was evidence of panellist uncertainty re-
garding the feasibility of KPI measurement (median
ratings of 4–6 on question 3), KPIs have to be deemed im-
portant and highly likely to be used as indicators for qual-
ity improvement (median ratings ≥7 on a 9-point scale
with no disagreement) to be included in the final set.
Results
Establishing measurement priorities (Phase 1)
An overview of the process used to establish measure-
ment priorities is shown in Fig. 1. In summary, the
major strategic decisions made regarding the scope of
the measures included the following:
1. The KPIs were selected to capture important steps
along the continuum of care between referral
submission to diagnosis and treatment (see Fig. 2).
The stakeholders acknowledged that guidelines
and high-quality evidence might be lacking for
measurement of some of the candidate KPIs
(e.g., measuring time from receipt of referral to
completion, or measuring patient or provider
experience with centralized intake). Therefore,
professional consensus was deemed an acceptable
Fig. 2 Example of a patient flow diagram for patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA) who are referred to
centralized intake. Musculoskeletal (MSK) referral screening: clerical review of incoming referrals to quickly identify if referrals are complete, and
which patients should be referred for a patient assessment to formally evaluate their MSK care needs. MSK referral triaging: review of screened
referrals to establish urgency and prioritize patients for patient assessment based on disease and severity of symptoms. MSK Specialty Care:
secondary care providers with MSK expertise, including specialists such as orthopaedic surgeons, rheumatologists, physiotherapists and nurses.
MSK Specialist Care: subset of specialty care providers (i.e., specialized physicians, orthopaedic surgeons and rheumatologists). DMARD biologic and
nonbiologic disease-modifying antirheumatic drug
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level of evidence for development and inclusion of
such candidate KPIs.
2. Although the stakeholders anticipate that, by
improving access to care and treatment, patient
outcomes will improve, measurement of long-term
patient outcomes was felt to be outside the scope of
the present project.
3. Although all dimensions of quality of care were
considered, safety indicators (such as drug
monitoring) would not be part of the final KPI set.
This decision was made because the role of
centralized intake is to facilitate access to the most
appropriate provider in a timely fashion, but it does
not necessarily include treatment of patients and
subsequent safety monitoring.
As a result of Phase 1, 25 KPIs were suggested for fur-
ther development based on the criteria for prioritization
and the strategic decisions listed above.
Integrative literature review (Phase 2)
Thirteen KPIs were harmonized with existing measures
(see Table 1 for measure sources). The remainder of the
KPIs were supported by guidelines or evidence support-
ing best practices for centralized intake found in our in-
tegrative review (full review results available upon
request).
Online modified Delphi procedure to finalize KPIs (Phase 3)
The candidate set submitted for panel evaluation is
shown in Table 1. It included KPIs to address perform-
ance of centralized intake in the following categories:
seven OA-specific KPIs, ten RA-specific KPIs and eight
KPIs that apply to centralized intake systems for both
conditions.
Response rates and participant demographics
Twenty-four (85.7 %) of the twenty-eight invitees partici-
pated in round 1 of the modified Delphi process, and
twenty-three (82.1 %) participated in round 3. Four par-
ticipants participated in round 1 but not in round 3, and
three participants participated in round 3 but not in
round 1. In total, 27 (96.4 %) of the 28 invitees partici-
pated in at least one round. During round 2, 12 partici-
pants (42.9 %) contributed to the online platform
discussion and 19 (67.9 %) contributed during the in-
person meeting. One of the participants who partici-
pated in the online discussion was not present at the
meeting, so the total participation rate during round 2
was 20 (71.4 %).
Twenty-six participants (93 %) provided basic demo-
graphic information: ten (39 %) were physicians (four
primary care physicians, four rheumatologists and two
orthopaedic surgeons); three were patient representatives,
including some patient engagement researchers (12 %); one
was a triage nurse (4 %); four were researchers (15 %); four
were healthcare managers (15 %); and four described them-
selves as ‘other’ (15 %). Twenty-five participants provided
information about their geographic area. Eleven were from
Calgary (44 %), nine were from Edmonton (36 %) and five
were from other regions in Alberta (20 %).
Results from online provincial panel to finalize KPIs
(Phase 3, round 2)
During the round 2 in-person meeting, the results from
round 1 and the online discussion part of round 2 were
reviewed (data available upon request). Based on discus-
sion of the results of these previous rounds, some modi-
fications to the KPI set were made (Table 1). Three of
the original KPIs were removed from the final round of
voting by consensus. KPI 9 (orthopaedic surgeons per
100,000 population) was excluded because panellists felt
there were better ways of capturing surgical capacity;
they suggested alternate KPIs (see description below for
KPIs 26 and 27). KPI 15 (percentage of RA referrals
assessed using a priority tool) was excluded due to con-
cerns of overly burdening the referring physicians. KPI
16 (percentage of RA referrals categorized as early RA)
was excluded, as it was deemed not sufficiently import-
ant and was superseded by the other KPIs relating to
wait times to receive care.
The panellists also recommended a number of new
KPIs that more effectively captured the measurement
priorities. KPI 26 (ratio of patient flow to estimated
clinic capacity of OA teams participating in centralized
intake) and KPI 27 (operating room time for arthroplasty
surgeons in Alberta) were added to more adequately re-
flect the capacity for complex OA care. Together, they
replaced the number of orthopaedic surgeons per
100,000 population (KPI 9). The analogous RA KPI—r-
heumatologists per 100,000 population (KPI 10)—was
still included because of greater concern regarding
rheumatologist capacity to provide high-quality RA care.
An additional RA indicator, KPI 28 (ratio of patient flow
to clinic capacity of RA teams participating in central-
ized intake) was added to capture clinic capacity.
To capture acceptability of centralized intake, the ori-
ginal set of KPIs included three indicators (KPIs 23–25)
that measured the patient, referring clinician and arth-
ritis specialty provider’s experience with the centralized
intake system. The panellists felt that the administrative
staff and allied health professionals should also be in-
cluded in a separate indicator and thus suggested KPI 29
(administrative staff and allied health professional
experience with centralized intake).
The panellists related that an important function of
centralized intake is ensuring that patients are appropri-
ately triaged based on the suspected diagnosis and the
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Table 1 Key performance indicators for musculoskeletal centralized intake
















3. Percentage of osteoarthritis referrals received with complete
information
Efficiency Hip and Knee Replacement
Measurement Frameworka,b
Included
4. Percentage of rheumatoid arthritis referrals received with complete
information
Efficiency New KPI Included
5. Time from receipt of complete osteoarthritis referral to musculoskeletal
appointment
Accessibility Hip and Knee Replacement
Measurement Frameworka,b
Included
6. Waiting times for rheumatologist consultation for patients with new-
onset rheumatoid arthritis
Accessibility AAC Performance measures
for IAc
Included







8. Percentage of patients with new-onset rheumatoid arthritis with at
least one visit to a rheumatologist in the first year of diagnosis
Accessibility AAC Performance measures
for IAc
Included
9. Orthopaedic surgeons per 100,000 population Accessibility COAd,e, AAOSf, ACREUe,g Removed
10. Rheumatologists per 100,000 population Accessibility AAC Performance measures
for IAc
Included
11. Percentage of patients that receive information regarding resources
and tools available for management while waiting for first
musculoskeletal specialty contact
Appropriateness Hip and Knee Replacement
Measurement Frameworka,b
Included
12. Percentage of osteoarthritis referrals scored using Western Canada
Waiting List priority referral criteriah
Appropriateness New KPI Included
13. Distribution of osteoarthritis referrals in each urgency category (as
scored using the Western Canada Waiting List referral tool)
Appropriateness New KPI Included
14. Percentage of osteoarthritis referrals triaged as highest urgency based
on high Western Canada Waiting List priority criteria scores seen within
Wait Time Alliance benchmarks
Appropriateness New KPI Included
15. Percentage of rheumatoid arthritis referrals assessed using a priority
tool
Appropriateness New KPI Removed
16. Percentage of rheumatoid arthritis referrals categorized as early
rheumatoid arthritis
Appropriateness New KPI Removed
17. Waiting times for patients with established rheumatoid arthritis Accessibility New KPI Included
18. Percentage of rheumatoid arthritis patients treated with a disease-






19. Percentage of referrals rejected or redirected when received at
centralized intake
Appropriateness New KPI Included
20. Percentage of musculoskeletal appointments completed as scheduled Efficiency Hip and Knee Replacement
Measurement Frameworka,b
Included
21. Percentage of specialist providers participating in centralized intake Efficiency New KPI Included
22. Number of referrals received through centralized intake Efficiency New KPI Included
23. Patient experience with centralized intake Acceptability AHRQi, NHSj, and Ministry of
Health and Long-Term Care
(Ontario)k
Included
24. Referring clinician experience with centralized intake Acceptability The Ministry of Health and
Long-Term Care (Ontario)k
Included
25. Musculoskeletal specialty care provider experience with centralized
intake
Acceptability The Ministry of Health and
Long-Term Care (Ontario)k
Included
26. Ratio of patient flow to estimated clinic capacity of osteoarthritis
teams participating in centralized intake
Efficiency,
accessibility
Developed during round 2 N/A
27. Operating room time for arthroplasty surgeons in Alberta Accessibility Developed during round 2 N/A
Barber et al. Arthritis Research & Therapy  (2015) 17:322 Page 6 of 12
Table 1 Key performance indicators for musculoskeletal centralized intake (Continued)
28. Ratio of patient flow to clinic capacity of rheumatoid arthritis teams
participating in centralized intake
Efficiency,
accessibility
Developed during round 2 N/A
29. Administrative staff and allied health professional experience with
centralized intake
Acceptability Developed during round 2 N/A
30. Agreement of centralized intake suspected diagnosis of severe
osteoarthritis cases (e.g., patients who are candidates for hip or knee joint
replacements) versus confirmed diagnosis of severe osteoarthritis
Appropriateness,
effectiveness
Developed during round 2 N/A
31. Agreement of centralized intake suspected diagnosis versus confirmed
diagnosis for rheumatoid arthritis
Appropriateness,
effectiveness
Developed during round 2 N/A
Total number of candidate




AAC Arthritis Alliance of Canada, IA Inflammatory Arthritis, AAOS American Academy of Orthopaedic Surgeons, ACREU Arthritis Community Research and
Evaluation Unit, AHRQ Agency for Healthcare Research and Quality, COA, Canadian Orthopaedic Association, NHS, National Health Service
aFrank et al. [27]
bMarshall et al. [39]
cBarber et al. [26]
dRumble and Kreder [40]
eBadley et al. [17]
fNatividad [41]
gCanizares et al. [42]
hThe Western Canada Waiting List (WCWL) Project has developed and validated a hip and knee replacement priority criteria tool to assess clinical urgency for hip
and knee joint replacements in a standardized and reliable manner [43]. The hip and knee replacement priority criteria tool is a clinician-scored tool consisting of
seven items: (1) pain on motion, (2) pain at rest, (3) ability to walk, (4) other functional limitations, (5) abnormal findings, (6) potential for progression of disease
and (7) ability to work, give care to dependents and live independently. The urgency is determined through a point count scoring system and could be used to
structure and manage waiting lists for hip and knee joint replacements [44]
iCamacho et al. [45]
jClinical Indicators Team [46]
kDeloitte & Touche LLP and affiliated entities [47]
Table 2 Final round 3 voting on ten rheumatoid arthritis–specific key performance indicators for centralized intake
Median (range) and percentage of participants voting ≥7 on 1–9 scale for each domain
(n = 23 unless otherwise specified)
Scientific
validity




KPI 2: Time from RA referral receipt to referral
completion for initially incomplete referrals
7 (5–8), 61 % 7 (6–8), 74 % 8 (6–8), n = 22 (64 %) 8 (7–8), 78 % 7 (6–8), 65 %
KPI 4: Percentage of RA referrals received with
complete information
7 (7–8), 78 % 8 (7–8), 83 % 7 (6–8), n = 22 (59 %) 8 (7–8), n = 22
(82 %)
7 (6–8), n = 22
(68 %)
KPI 6: Waiting times for rheumatologist consultation
for patients with new-onset rheumatoid arthritis
N/Aa N/Aa 8 (8–9), n = 21 (95 %) 9 (8–9), n = 22
(100 %)
9 (9–9), n = 22
(100 %)
KPI 7: Time to disease-modifying antirheumatic
drug therapy for patients with new-onset RA
N/Aa N/Aa 7 (6–8), n = 22 (68 %) 9 (8–9), 91 % 9 (8–9), n = 22
(100 %)
KPI 8: Percentage of patients with new-onset RA
with at least one visit to a rheumatologist in the
first year of diagnosis
N/Aa N/Aa 7 (6–8), n = 21 (57 %) 8 (7–9), 78 % 8 (7–8), 83 %
KPI 10: Rheumatologists per 100,000 population N/Aa N/Aa 7 (6–8), n = 21 (62 %) 7 (6–7), n = 22
(59 %)
7 (5–7), n = 21
(52 %)
KPI 17: Waiting times for patients with
established RA
8 (8–9), 96 % 9 (8–9), 96 % 8 (7–8), n = 22 (77 %) 8 (8–9), 91 % 8 (8–9), 96 %
KPI 18: Percentage of rheumatoid arthritis patients
treated with a disease-modifying antirheumatic
drug during the measurement year
N/Aa N/Aa 8 (6–9), 70 % 8 (8–9), 83 % 9 (8–9), 83 %
KPI 28: Ratio of patient flow to clinic capacity of
RA teams participating in centralized intake
7 (6–8), n = 22
(73 %)
8 (7–8), n = 22
(82 %)
7 (5–8), n = 22 (55 %) 7 (7–8), 83 % 8 (7–9), n = 22
(86 %)
KPI 31: Agreement of centralized intake suspected
diagnosis versus confirmed diagnosis of RA
8 (6–8), n = 21
(71 %)
8 (6–8), 74 % 7 (5–8), n = 22 (55 %) 8 (7–9), n = 22
(86 %)
8 (7–9), n = 21
(76 %)
RA rheumatoid arthritis
aKey performance indicators (KPIs) 6, 7, 8, 10 and 18 were harmonized with the Arthritis Alliance of Canada performance measure set for inflammatory arthritis
which used a similar process for development and scientific validity and face validity were not examined again in the present study
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information provided on the referral form. To assess
this, KPIs related to the degree of agreement between
the centralized intake suspected diagnosis and the spe-
cialist’s final diagnosis were suggested by the panellists
to be a critical component for evaluating the effective-
ness of triage. Thus, two new indicators were added to
evaluate the diagnostic agreement, one each for OA
(KPI 30) and RA (KPI 31).
Final round 3 voting
A total of 28 KPIs were submitted for final voting in
round 3. Ten RA-specific KPIs (Table 2), nine OA-
specific KPIs (Table 3) and nine KPIs applied to central-
ized intake systems for both conditions (Table 4). All ten
RA KPIs were rated as valid, feasible and important,
with a high perceived likelihood of use (median ratings
≥7 on a 9-point scale) and no disagreement according to
the IPR > IPRAS rule. Similarly, seven of the nine KPIs
for OA were rated highly in all domains, with two ex-
ceptions. KPI 12 (percentage of OA referrals scored
using Western Canada Waiting List (WCWL) [35] prior-
ity referral criteria) had median scores of 6 for face val-
idity and feasibility, and KPI 13 (distribution of OA
referrals in each urgency category scored using the
WCWL referral tool) had a median score of 6 in feasibil-
ity. Of the nine KPIs that applied to centralized intake
systems in general, there was uncertainty regarding the
feasibility of capturing three: KPI 11 (percentage of pa-
tients who receive information regarding resources and
tools available for management while waiting for first
musculoskeletal specialty contact), KPI 24 (referring cli-
nician’s experience with centralized intake) and KPI 25
(musculoskeletal specialty care provider experience with
centralized intake). All other KPIs had median scores ≥7
for validity, importance and likelihood of use, with no
disagreement.
Discussion
Through a rigorous process involving arthritis stake-
holders from across the Province of Alberta, we devel-
oped a set of 28 KPIs for evaluation of centralized intake
methods for OA and RA care. The KPIs address five di-
mensions of the provincial quality framework [23], with
the exception of safety, which was deemed outside the
scope of this project. Our panellists rated the KPIs as
highly valid and important. They also suggested that the
indicators were highly likely to be used in the evaluation
of centralized intake.
To our knowledge, this is the first set of KPIs specific-
ally designed to assess centralized intake systems for
arthritis care. Although developed within the context of
Alberta, the KPIs are likely highly relevant to other
Table 3 Final round 3 voting on nine osteoarthritis-specific key performance indicators for centralized intake
Median (range) and percentage of participants voting ≥7 on 1–9 scale for each
domain (n = 23 unless otherwise specified)
Scientific
validity




KPI 1: Time from OA referral receipt to referral
completion for initially incomplete referrals
7 (5–8), 65 % 7 (6–8), 74 % 8 (6–8), n = 22 (68 %) 8 (7–8), 78 % 7 (6–8), 74 %
KPI 3: Percentage of OA referrals received with
complete information
7 (6–8), 65 % 8 (7–8), 83 % 7 (6–8), n = 22 (73 %) 7 (7–8), 83 % 7 (6–8), n = 22
(64 %)
KPI 5: Time from receipt of complete OA referral
to musculoskeletal appointment
8 (8–9), 96 % 9 (8–9), 100 % 8 (7–9), n = 22 (86 %) 9 (8–9), n = 22
(100 %)
9 (8–9), n = 22
(95 %)
KPI 12: Percentage of OA referrals scored using
Western Canada Waiting List priority referral criteria
7 (6–7), n = 22
(73 %)
6 (6–8), n = 22
(45 %)
6 (5–7), n = 22 (45 %) 7 (6–7), n = 22
(64 %)
7 (6–7), n = 22
(59 %)
KPI 13: Distribution of OA referrals in each urgency
category (as scored using the Western Canada
Waiting List referral tool)
7 (7–8), 83 % 7 (6–8), 65 % 6 (6–7), n = 22 (50 %) 7 (6–8), 74 % 7 (6–8), 61 %
KPI 14: Percentage of OA referrals triaged as highest
urgency based on high Western Canada Waiting List
priority criteria scores seen within Wait Time Alliance
benchmarks
8 (7–8), 96 % 8 (7–8), 91 % 7 (6–7), n = 22 (59 %) 7 (7–8), n = 21
(95 %)
8 (7–8), 87 %
KPI 26: Ratio of patient flow to estimated clinic capacity
of OA teams participating in centralized intake
7 (6–7), n = 22
(64 %)
8 (7–8), 83 % 7 (5–7), n = 22 (55 %) 8 (7–9), n = 22
(82 %)
8 (7–9), n = 22
(82 %)
KPI 27: Operating room time for arthroplasty surgeons
in Alberta
7 (6–8), n = 20
(55 %)
7 (7–8), n = 22
(77 %)
7 (7–8), n = 20 (75 %) 7 (6–8), n = 21
(67 %)
7 (5–8), n = 21
(67 %)
KPI 30: Agreement of centralized intake suspected
diagnosis of severe OA cases (e.g., patients who are
candidates for hip or knee joint replacements) versus
confirmed diagnosis of severe OA
8 (7–8), n = 21
(81 %)
8 (7–8), n = 21
(90 %)
7 (6–8), n = 19 (63 %) 8 (8–9), n = 21
(95 %)
8 (8–9), n = 19
(89 %)
KPI key performance indicator, OA osteoarthritis
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arthritis and musculoskeletal care settings where central-
ized intake is feasible. The KPIs may also help to inform
improvements in healthcare systems interested in devel-
oping centralized intake systems, although such systems
may not be possible in all care settings (e.g., single-
practice settings). These KPIs may also be of interest to
other specialty services.
The KPIs presented herein focus on OA and RA, al-
though it was recognized that any centralized intake sys-
tem for arthritis care is likely to receive referrals for
other types of arthritis. OA and RA were chosen because
these are the two most common arthritis conditions in
the general population and represent prototypical in-
flammatory and non-inflammatory arthritis. There is
also strong evidence that better access to care and treat-
ment in these conditions leads to improved patient out-
comes [2, 3, 5–7, 36, 37].
During the KPI development process, we decided a
priori not to exclude KPIs with lower feasibility ratings
(median scores of 4–6), reflecting the panellists’ uncer-
tainty about the availability of information. We did not
want to exclude potentially important and relevant KPIs
for which system changes could be implemented in the
future to enable data capture. In total, two OA KPIs re-
lated to scoring the WCWL (KPIs 12 and 13), which is a
prioritization tool for hip and knee OA surgical consult-
ation [35], were rated as less feasible. During round 2
discussions, it became clear that although the WCWL is
included on current triage forms for hip and knee surgi-
cal referrals in Alberta, the tool is not empirically scored.
It was likely that panellists considered the feasibility of
scoring the WCWL in this environment as uncertain be-
cause technology changes would be needed to imple-
ment scoring of the WCWL. For similar reasons, the
face validity of KPI 12 was questioned (percentage of
OA referrals scored using the WCWL priority referral
criteria). That KPI was retained, however, because panel-
lists indicated that it was sufficiently important and that
they were highly likely to use it.
KPI 11 (percentage of patients who receive information
regarding resources and tools available for management
while waiting for first musculoskeletal specialty contact)
also received lower feasibility scores. This is likely because
there are few means of tracking which information pa-
tients receive while waiting for their appointment (beyond
appointment scheduling information), and changes to
existing clinical databases and triage processes would be
needed to capture this KPI.
Similarly, the KPIs related to the referring clinician or
specialty care provider (e.g., rheumatologist or ortho-
paedic surgeon) experience with centralized intake (KPIs
24 and 25) received lower feasibility ratings, as surveys
capturing clinician experience are not routinely done in
Alberta. Interestingly, there were higher ratings for KPIs
capturing the experience of patients as well as adminis-
trative staff and allied health professionals. This may be
Table 4 Final round 3 voting on nine key performance indicators for centralized intake applicable to rheumatoid arthritis and
osteoarthritis










KPI 11: Percentage of patients who receive information
regarding resources and tools available for management
while waiting for first musculoskeletal specialty contact
7 (7–8), 78 % 7 (7–8),
91 %
6 (4–6), n = 21 (24 %) 7 (7–8), n = 22
(86 %)
8 (7–8), n = 22
(77 %)
KPI 19: Percentage of referrals rejected or redirected
when received at centralized intake
7 (6–8), 74 % 7 (6–8),
70 %
7 (6–8), n = 21 (67 %) 7 (7–8), 83 % 7 (7–8), n = 22
(77 %)
KPI 20: Percentage of musculoskeletal appointments
completed as scheduled
7 (6–8), 65 % 8 (7–8),
87 %
7 (6–8), n = 22 (64 %) 9 (8–9), n = 21
(81 %)
8 (7–9), n = 22
(77 %)
KPI 21: Percentage of specialist providers participating
in centralized intake
7 (6–7), 70 % 7 (7–8),
78 %
7 (6–8), n = 22 (73 %) 8 (7–8), 83 % 7 (7–8), 83 %
KPI 22: Number of referrals received through centralized
intake
7 (7–8), 78 % 8 (7–8),
87 %
9 (7–9), n = 21 (81 %) 9 (8–9), 100 % 8 (7–9), n = 22
(95 %)
KPI 23: Patient experience with centralized intake 7 (7–8), 87 % 8 (8–9),
87 %
7 (5–8), 65 % 9 (8–9), n = 22
(95 %)
9 (8–9), 87 %
KPI 24: Referring clinician’s experience with centralized
intake
7 (7–8), 78 % 8 (7–8),
96 %
5 (5–7), 32 % 9 (8–9), 96 % 9 (7–9), 96 %
KPI 25: Musculoskeletal specialty care provider experience
with centralized intake
7 (6–8), 70 % 7 (7–8),
91 %
6 (5–7), n = 22 (45 %) 8 (7–9), 91 % 8 (7–9), 96 %
KPI 29: Administrative staff and allied health professional
experience with centralized intake




7 (5–7), n = 22 (59 %) 8 (7–9), 83 % 8 (7–9), n = 21
(76 %)
KPI key performance indicator
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because there are existing patient surveys already admin-
istered routinely in Alberta (especially for patients with
OA). Furthermore, it was felt that administrative staff
and allied health professionals were more easily surveyed
than referring or specialty physicians.
Conclusion
We developed a set of 28 KPIs for evaluation of central-
ized intake for patients with OA and RA. The KPIs will
be tested further for feasibility using existing data
sources (e.g., administrative data and clinical databases)
before widespread implementation. Once tested for
feasibility, the KPIs will be used to develop and evaluate
an optimal centralized intake system for arthritis care
for OA and RA. Measuring the impact of changes to a
centralized intake system using standardized metrics is
critical for ongoing quality assurance and quality im-
provement in health systems [38], and this work repre-
sents a critical first step in optimizing access to
healthcare delivery for patients with OA and RA.
Additional file
Additional file 1: Integrative literature review search strategy. The
search strategy used for an integrative review of literature to ensure
candidate key performance indicators were based on evidence and/or
best practices, and that they were harmonized with any existing
published performance measures. (DOCX 20 kb)
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